EJE. Niclas Jonsson

E. Niclas Jonsson

*This is an algorithmically generated author record based on publicly available information.

E. Niclas Jonsson has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Use of Full Random Effects Models in Model-Informed Precision Dosing

    by Marina Dimitriou, Siv Jönsson, E. Niclas Jonsson

    Background: Model-informed precision dosing (MIPD) uses mathematical models for a priori and a posteriori dose predictions. One of its challenges is how to handle missing covariate data. The purpose in this study was to compare the performance of Full Random Effects Models (FREM) against a reference fixed effect model (FEM) in handling varying missing covariate scenarios. Methods: Missing covariate data is typically addressed via mean imputation in FEM. Conversely, FREM treats covariates as observed data, allowing the derivation of FEM for any available covariate subset without parameter reestimation. To evaluate this, a reference FEM (REF) and a FREM were estimated using simulated data from an established population pharmacokinetic model across various residual unexplained variability and clearance interindividual variability levels. A priori and a posteriori dosing was evaluated for multiple covariate scenarios. Predictive performance was assessed using mean absolute relative prediction error and mismatch percentage between predicted and true doses. Results: For a priori predictions based on the covariates originally available in REF, performance was mostly comparable between FREM and REF. However, FREM demonstrated a performance advantage for a priori predictions when used to derive FEM that incorporated covariates not originally included in REF. A posteriori performance, which also depends on the available data, across all scenarios was similar between FREM and REF. Conclusions: FREM-derived FEM provide a performance edge for a priori dose predictions by using additional covariates that were not originally included in REF, whereas both methods perform similarly for a posteriori predictions. Overall, FREM seems to offer a more flexible approach for MIPD when covariate availability varies.

  • Open Access

    Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling

    by E. Niclas Jonsson, Joakim Nyberg, France Mentré

    Pharmacometric covariate analyses support both mechanistic understanding and clinical decision‐making, that is, two different objectives which require different analysis targets. Adopting the ICH E9(R1) estimand framework clarifies this distinction, reconciling mechanistic modeling (conditional covariate effects) with regulatory and clinical needs (unconditional covariate effects), clarifying that estimand definition, i.e. the objective, and not the estimator, is the first choice to make in covariate modeling. This structured approach optimizes quantitative evidence for communicating clinical impact and patient care.

  • Open Access

    Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting

    by E. Niclas Jonsson, Siv Jönsson, Emma Hansson, Joakim Nyberg

    This work investigates how correlations between covariates influence the estimation of their effects in pharmacometric models. The focus is on quantifying the impact on conditional and unconditional covariate effect estimates and assessing the consequences for model interpretation, communication, and dosing recommendations. A theoretical framework was used to describe the mathematical relationship between conditional and unconditional coefficients. This was verified by simulations across a wide range of covariate correlation strengths and relative covariate effect sizes. The practical consequences of misinterpreting conditional effects were evaluated in the context of dose selection and a priori dose individualization. As predicted by theory, covariate correlation had a substantial effect on the conditional covariate coefficient estimates, while unconditional estimates remained stable. Interpreting conditional covariate effects in isolation led to incorrect conclusions about dosing needs and introduced bias and imprecision in individual dose predictions. In contrast, both the complete conditional model and the unconditional model gave accurate predictions when applied appropriately. Unconditional covariate effects offer greater interpretability, making them more suitable for communicating individual covariate impacts in drug labels, publications, and forest plots. We demonstrate that conditional effects are highly sensitive to model context and covariate correlation, making them poor proxies for the unconditional effect, which is often the quantity of interest for dosing and communication. To minimize misinterpretation, unconditional effects should be reported when describing the influence of individual covariates, while the complete conditional model should be used for simulations and exposure predictions. This dual approach can improve clarity and reduce the risk of misunderstanding in model‐informed decision‐making.


  • Open Access

    Conditional versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting

    by Niclas Jonsson, Siv Jönsson, Emma Hansson, Joakim Nyberg

    Aim This work investigates how correlations between covariates influence the estimation of their effects in pharmacometric models. The focus is on quantifying the impact on conditional and unconditional covariate effect estimates and assessing the consequences for model interpretation, communication, and dosing recommendations. Methods A theoretical framework was used to describe the mathematical relationship between conditional and unconditional coefficients. This was verified by simulations across a wide range of covariate correlation strengths and relative covariate effect sizes. The practical consequences of misinterpreting conditional effects were evaluated in the context of dose selection and a priori dose individualization. Results As predicted by theory, covariate correlation had a substantial effect on the conditional covariate coefficient estimates, while unconditional estimates remained stable. Interpreting conditional covariate effects in isolation led to incorrect conclusions about dosing needs and introduced bias and imprecision in individual dose predictions. In contrast, both the complete conditional model and the unconditional model gave accurate predictions when applied appropriately. Conclusions Unconditional covariate effects offer greater robustness and interpretability, making them more suitable for communicating individual covariate impacts in drug labels, publications, and forest plots. To minimize misinterpretation, unconditional effects should be reported when describing the influence of individual covariates, while the complete conditional model should be used for simulations and exposure predictions. This dual approach can improve clarity and reduce the risk of misunderstanding in model-informed decision-making.

  • Open Access

    The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models

    by Joakim Nyberg, E. Niclas Jonsson

    Identification of covariates that can explain sources of variability among individuals in pharmacometric models is key, as it can lead to patient-subgrouping or patient-specific dosing strategies. Common recommendations propose to limit the covariate-parameters relationships to be tested to those that are scientifically plausible, a process called covariate “scope reduction”. We investigated the possible impact of scope reduction on model parameters estimated with misspecified models in terms of omission bias (when a relevant covariate is not included in a model) and inclusion bias (when a non-relevant covariate is included). One-hundred datasets were simulated with a rich-sampling design using 8 variations of a one-compartment model with first-order absorption, having clearance (CL), volume of distribution (V), and absorption rate constant (Ka) as parameters, and body weight (WT) as covariate. Parameters were estimated using 14 models that included the covariate using fixed-effects (FEM) and 2 full random-effects models (FREM), with combinations of covariate-parameter relationships and IIV correlations. Estimated parameters were compared to the parameter values used for simulations in terms of accuracy (bias) and precision. Results showed that, in misspecified FEMs, covariate coefficients and IIV parameters were sensitive to omission bias. Conversely, misspecified covariate models did not introduce inclusion bias since the impact of a non-relevant covariate was estimated, as expected, to values close to zero, and in these cases FREM performed better than FEM. In conclusion, while inclusion bias does not seem to be an issue in misspecified models, the risk of introducing omission bias in parameter estimates should be kept in mind when considering covariate scope reduction when covariate models are implemented using fixed effects.


  • Population pharmacokinetic and dose–response models of nepadutant, a selective antagonist of the NK2 receptors, in infants with colic

    by Siv Jönsson, Salim Bouchene, Paolo Mazzei, Elisa Borella, Chiara Piana, Alessia Tagliavini, Sibylle Koletzko, Katharina Werkstetter, Angela Capriati, Andrea Pellacani, et al.

    Aims: The aim of the current analyses was to develop a population pharmacokinetic model for nepadutant in infants with colic, and a pharmacokinetic‐pharmacodynamic model based on observations of duration of crying and fussing following oral nepadutant administration in infants (3–25 weeks) with colic.Methods: The models were developed based on data obtained at baseline and following treatment with placebo, nepadutant 0.1 mg/kg or nepadutant 0.5 mg/kg administered for 7 days. A continuous response variable, duration of crying and fussing in minutes within 2 h interval, was assembled based on records from “baby's day” diary.Results: The pharmacokinetics of nepadutant was described by a one‐compartment model with first‐order absorption and elimination with body weight as a structural covariate incorporated allometrically. For an infant weighing 5.3 kg, the estimated apparent clearance was 68.6 L/h (12% relative standard error) and exhibited large variability (78% coefficient of variation). The pharmacokinetic‐pharmacodynamic model described (i) a circadian rhythm in the response with lowest and highest observations at 4 a.m. and 9 p.m., respectively, (ii) a placebo effect increasing and flattening out with time in an exponential manner, and (iii) a statistically significant (P < .01) linearly increasing response with dose. The observed and model predicted relative change in response from baseline was −35% and −28% (95% prediction interval −36%; −19%) following placebo, and −44% and −36% (−46%; −27%) after 0.5 mg/kg.Conclusions: Population pharmacokinetic and dose–response models were successfully developed characterizing the available nepadutant pharmacokinetics and duration of crying and fussing data in infants.


  • Open Access

    Full random effects models (FREM): A practical usage guide

    by E. Niclas Jonsson, Joakim Nyberg

    The full random‐effects model (FREM) is an innovative and relatively novel covariate modeling technique. It differs from other covariate modeling approaches in that it treats covariates as observations and captures their impact on model parameters using their covariances. These unique characteristics mean that FREM is insensitive to correlations between covariates and implicitly handles missing covariate data. In practice, this implies that covariates are less likely to be excluded from the modeling scope in light of the observed data. FREM has been shown to be a useful modeling method for small datasets, but its pre‐specification properties make it a very compelling modeling choice for late‐stage phases of drug development. The present tutorial aims to explain what FREM models are and how they can be used in practice.


  • Open Access

    Using forest plots to interpret covariate effects in pharmacometric models

    by E. Niclas Jonsson, Joakim Nyberg

    The inclusion of covariates in pharmacometric models is important due to their ability to explain variability in drug exposure and response. Clear communication of the impact of covariates is needed to support informed decision making in clinical practice and in drug development. However, effectively conveying these effects to key stakeholders and decision makers can be challenging. Forest plots have been proposed to meet these communication needs. However, forest plots for the illustration of covariate effects in pharmacometrics are complex combinations of model predictions, uncertainty estimates, tabulated results, and reference lines and intervals. The purpose of this tutorial is to outline the aspects that influence the interpretation of forest plots, recommend best practices, and offer specific guidance for a clear and transparent communication of covariate effects.


  • Open Access

    Properties of the full random‐effect modeling approach with missing covariate data

    by Joakim Nyberg, E. Niclas Jonsson, Mats O. Karlsson, Jonas Häggström

    During drug development, a key step is the identification of relevant covariates predicting between‐subject variations in drug response. The full random effects model (FREM) is one of the full‐covariate approaches used to identify relevant covariates in nonlinear mixed effects models. Here we explore the ability of FREM to handle missing (both missing completely at random (MCAR) and missing at random (MAR)) covariate data and compare it to the full fixed‐effects model (FFEM) approach, applied either with complete case analysis or mean imputation. A global health dataset (20 421 children) was used to develop a FREM describing the changes of height for age Z‐score (HAZ) over time. Simulated datasets (n = 1000) were generated with variable rates of missing (MCAR) covariate data (0%‐90%) and different proportions of missing (MAR) data condition on either observed covariates or predicted HAZ. The three methods were used to re‐estimate model and compared in terms of bias and precision which showed that FREM had only minor increases in bias and minor loss of precision at increasing percentages of missing (MCAR) covariate data and performed similarly in the MAR scenarios. Conversely, the FFEM approaches either collapsed at 70% of missing (MCAR) covariate data (FFEM complete case analysis) or had large bias increases and loss of precision (FFEM with mean imputation). Our results suggest that FREM is an appropriate approach to covariate modeling for datasets with missing (MCAR and MAR) covariate data, such as in global health studies.


  • Open Access

    Writing reports of modelling and simulation analysis: Our experience in the field of pharmacometrics

    by Viviana Moroso, Mats O. Magnusson, E. Niclas Jonsson

    Pharmacometric analyses generate mathematical models that can describe and simulate the pharmacokinetics and pharmacodynamics of drugs. The role of these modelling and simulation (M&S) analyses is growing both in drug development and regulatory assessment. Reporting M&S analyses can be technically challenging given the large amount of input and output data that need to be summarised and accurately described in regulated reports. Therefore, reproducibility, automation, traceability, and standardisation are considered key aspects of this process. We present here a system that, using a combination of software, meets these challenges and improves the efficiency, accuracy, and reliability of our work. Medical Writing. 2023;32(3):56–63. https://doi.org/10.56012/wmqy8556